TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05152264

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Description: Treatment with transcutaneous electrical nerve stimulation (TENS) during 16 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Description: Treatment with transcutaneous electrical nerve stimulation (TENS) during 16 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional analgesic treatment
Description: Conventional analgesic treatment. Conventional analgesic treatment may include no pharmacological treatment if the patient does not use any analgesics.
Study: NCT05784961

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: tDCS will be delivered using this electrode montage: anode on the left dosolateral prefrontal cortex (L DLPFC) using F3 EEG landmark and cathode on the left temporoparietal junction (L TPJ) on the middle point between T3 and P3 EEG landmark.~The stimulation will be delivered at an intensity of 2 milliamps, for 20 minutes, five times a day, with 20 min inter sessions (it will be carried out on 5 consecutive days from Monday to Friday). Each processing day corresponds to a visit of V2, V3, V4, V5 and V6.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: tDCS
Description: tDCS will be delivered using this electrode montage: anode on the left dosolateral prefrontal cortex (L DLPFC) using F3 EEG landmark and cathode on the left temporoparietal junction (L TPJ) on the middle point between T3 and P3 EEG landmark.~The stimulation will be delivered at an intensity of 2 milliamps, for 20 minutes, five times a day, with 20 min inter sessions (it will be carried out on 5 consecutive days from Monday to Friday). Each processing day corresponds to a visit of V2, V3, V4, V5 and V6.
Study: NCT06411561

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SLEEP + COG
Description: Combination of SLEEP and COG interventions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COG
Description: Daily 30-minute session of computerized cognitive training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SLEEP
Description: Nighttime use of both ear plugs and eye masks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: AC
Description: Educational modules on cognitive and sleep health
Study: NCT06425536

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home use
Description: Home use twice a day
Study: NCT06556602

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MPACT
Description: Four components are part of this intervention: 1) accredited training about patient centered, trauma-informed care and the standard of care under the current federal regulation (42CFRpart8), 2) education about trauma and trauma symptoms including vicarious (work related) trauma and navigation to symptoms screening and resources including treatment, 3) reflective supervision for counseling, case management and peer staff, and 4) clinic self assessment for trauma-informed and patient centered care
Study: NCT05861973

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptive SMARTer intervention (SMARTer)
Description: Participants will receive calorie, fat, and physical activity goals, a Smartphone application for self-monitoring their diet, activity and weight, online educational readings, and brief bi-weekly remote health sessions with a Health Promotionist. They will also be loaned a Fitbit tracking device and a wireless bluetooth scale for 6 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Prevention Program Participants (DPP)
Description: In accordance with the Center for Disease Control curriculum, participants will receive a participant log for tracking physical activity, food intake, and weight, a paper participant guide with worksheets, logs, and psycho-educational materials, and 16 hour long remote sessions with a Health Promotionist.
Study: NCT05643287

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal treatment
Description: Non-surgical periodontal treatment
Study: NCT06610032

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mesotherapy
Description: A total of 3 sessions of mesotherapy will be applied to the shoulder area of the patients, 7 days apart in group 1.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intra-articular steroid injection
Description: Single session intra-articular 20 mg triamcinolone hexacetonide injection will be applied for patients in group 2.
Study: NCT06664957

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C (Ascorbic Acid)
Description: Participants in this arm will receive 400 mg of Vitamin C, administered as two 100 mg tablets in the morning and two 100 mg tablets in the evening, for a total of 12 months. The intervention aims to support antioxidant defense and improve clinical outcomes in COPD patients.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in this group will receive a placebo, identical in appearance to the active nutrient supplement (Vitamin C) tablets, with no active ingredients. The placebo will be administered as two tablets in the morning and two tablets in the evening (four tablets per day) for a duration of 12 months, serving as a control to compare the effects of the active intervention.
Study: NCT06615141

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oculus Quest 3
Description: Oculus quest 3 is a standalone virtual reality headset developed by Meta. It offers precise motion tracking and offers an innovative intervention for stroke rehabilitation, enhancing upper limb motor function throug task - specific exercises.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neofect Smartboard and Tyromotion Myro
Description: Neofect Smart Board provides non-immersive VR rehabilitation through gamified, task specific exercises to improve upper limb mobility in an interactive way.~Tyromotion Myro uses non-immersive VR therapy combining sensor-based feedback and interactive games to enhance fine motor skills.
Study: NCT06602726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN1908
Description: Administered per the protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN1909
Description: Administered per the protocol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered per the protocol
Study: NCT05748600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexpramipexole Dihydrochloride
Description: administration of dexpramipexole tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexpramipexole Dihydrochloride
Description: administration of dexpramipexole tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administration of placebo tablet
Study: NCT06559995

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ketone supplement D-beta-hydroxybutryric acid and R-1,3 butanediol 12g of ketones,
Description: ketone supplement

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: magnetic resonance imaging session
Description: 1.5 hour magnetic resonance imaging session

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: magnetic resonance imaging session
Description: 1.5 hour magnetic resonance imaging session

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo beverage
Description: Placebo beverage, visually matched, three times a day before meals, by mouth for 4 days plus 1 dose on day 5 for magnetic resonance imaging session visit.
Study: NCT05748626

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anti-snoring device
Description: For group 1, the study team will aid the subject in molding and preparing the device in the pre-operative area. They will wear the device throughout the entirety of the case.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No anti -snoring device during their procedure.
Description: For group 2 there will be no anti snoring device used during the case.
Study: NCT05812638

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental imagery technique
Description: Warm up Period Mental Imagery (Sit-stand task Static stance (30 seconds) Indoor walk on a leveled surface Walk indoor towards target Forward / Side Stepping) Walk outdoors

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality technique
Description: Virtual reality training (River rush, 20000 water leaks, reflex ridge.)
Study: NCT05206838

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical reconstruction of gluteus medius with Achilles tendon allograft
Description: Achilles tendon allograft i fixed between the gluteus medius muscle and the greater trochanter
Study: NCT05493163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thrombolytic
Description: Local, catheter-directed thrombolysis with a total dose of 10mg per affected lung administered over 9 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard anticoagulation
Description: Standard anticoagulation therapy of acute pulmonary embolism.
Study: NCT05705869

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: NT-proBNP
Description: NT-proBNP will be measured in all participants in the Investigational arm. If the level of the NT-proBNP is elevated (≥125pg/mL) participants will undergo a full cart-based transthoracic echocardiogram along with a clinical examination for signs of HF and a HF symptom assessment. Participants with HF identified will be referred to their local HF clinic for ongoing management.
Study: NCT06139133

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplementation
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Description: Vitamin D3 supplementation (2 00,000 IU/Week)
Study: NCT06558968

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: aesthetic functional space maintainers
Description: evaluate the use of Polyetheretherketone 'PEEK' and monolithic zirconia 'Bruxzir' as esthetic functional band and loop space maintainers.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: aesthetic functional space maintainers
Description: evaluate the use of Polyetheretherketone 'PEEK' and monolithic zirconia 'Bruxzir' as esthetic functional band and loop space maintainers.
Study: NCT05661591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR2554 Tablets
Description: SHR2554 Tablets+ Fluconazole Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole Capsules
Description: SHR2554 Tablets+ Fluconazole Capsules
Study: NCT06120153

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: POC PCR-test device
Description: The analysis will follow an intention-to-treat principle, that is, contacts in the intervention period will be analyzed as randomized, regardless of whether the POC PCR test was actually performed for a given contact. As sensitivity analysis, the data will be analyzed in a per-protocol spirit, defining the intervention at the contact level as a POC PCR test performed.
Study: NCT06685146

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucagon Infusion
Description: A 240 minutes infusion of glucagon (10 ng/kg/min)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose clamp
Description: A 240 minutes infusion of 20 % w/v glucose. The infusion rate of glucose will be adjusted continuously to match the levels of glucose measured on the glucagon study day.
Study: NCT05544123

Intervention type: OTHER
Intervention: pathological stage
Description: breast cancer molecular subtyping and pathological TNM stage
Study: NCT04824066

Intervention type: DEVICE
Intervention: Device: Wearable Device
Description: A Wearable Device will be placed on the wrist of the patient \~30 days prior to the patient's scheduled surgery, removed during the operation, and replaced for \~180 days post-operatively. The device will record activity in terms of steps, sleep quality, heart rate, etc.
Study: NCT06686797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-08049820
Description: Oral solution/suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-08049820
Description: Oral solution/suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-08049820
Description: Oral solution/suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral solution/suspension
Study: NCT06063031

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Active
Description: Active nutritional supplement plus telerehabilitation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo nutritional supplement plus telerehabilitation
Study: NCT06351189

Intervention type: DEVICE
Intervention: Observation
Description: Patients will be filmed in sitting position in the NETTI DYNAMIC chair, either in static mode or dynamic mode for a period of 3 hours each time.

Intervention type: DEVICE
Intervention: Observation
Description: Patients will be filmed in sitting position in the NETTI DYNAMIC chair, either in static mode or dynamic mode for a period of 3 hours each time.
Study: NCT06559969

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous administered opioid
Description: Hydromorphone will be received intravenously using a patient controlled administration pump, as well as patient will have a continuous bupivacaine epidural infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidural administered opioid
Description: Hydromorphone will be added to the bupivacaine in the epidural and will have a continuous infusion along with the ability for the patient to receive epidural boluses of the medications by a patient controlled epidural administration pump
Study: NCT05639647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATM-AVI
Description: A drug specifically designed to treat resistant gam-negative bacterial infections

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BAT
Description: BAT will be selected by the investigator and administered iv as appropriate for the selected drug(s)
Study: NCT05261139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nirmatrelvir
Description: PF-07321332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nirmatrelvir
Description: PF-07321332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nirmatrelvir
Description: PF-07321332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nirmatrelvir
Description: PF-07321332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nirmatrelvir
Description: PF-07321332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: ritonavir
Study: NCT05704036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal estrogen
Description: Transdermal estradiol 0.1 mg/day, applied once weekly
Study: NCT05544123

Intervention type: OTHER
Intervention: pathological stage
Description: breast cancer molecular subtyping and pathological TNM stage

Intervention type: OTHER
Intervention: pathological stage
Description: breast cancer molecular subtyping and pathological TNM stage

Intervention type: OTHER
Intervention: pathological stage
Description: breast cancer molecular subtyping and pathological TNM stage
Study: NCT05971394

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System (IBS Titan™)
Description: Subjects in this arm will be treated with Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System (IBS Titan™)
Study: NCT05704036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Progesterone 200 mg daily for 10 days/month, if participant is not on progesterone-containing contraceptive
Study: NCT06420076

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD5/CD7 CAR-T
Description: The intervention in this clinical trial involves a novel approach using CD5/CD7 Chimeric Antigen Receptor T (CAR T) cells combined with chemotherapy. The goal is to assess safety and efficacy in patients with specific hematologic malignancies.~Treatment Regimen:~Patients in the trial will undergo the following regimen:~Fludarabine Phosphate (Days -4 to -2): IV administration of fludarabine phosphate over 30 minutes on days -4 to -2. It's part of the preparatory regimen to enhance the body's response to CAR T-cell therapy.~Cyclophosphamide (Day -2): IV cyclophosphamide over 60 minutes on day -2.~CD5/CD7 Chimeric Antigen Receptor T Cells (Day 0): IV administration of investigational therapy, CD5/CD7 CAR T cells, over 10-20 minutes on day 0.~Additional Doses: Eligible patients responding well to the initial CD5/CD7 CAR-T cell infusion without unacceptable side effects and sufficient CAR-T cell availability may receive 2 or 3 additional doses.
Study: NCT04651296

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: compassion meditation
Description: manualized compassion meditation training
Study: NCT06686797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral solution/suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral solution/suspension
Study: NCT06696326

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: standard-of-care imaging 68Ga-MY6349 and 68Ga-PSMA-11
Description: Each subject receives a single intravenous injection of standard-of-care imaging radiopharmaceuticals 68Ga-MY6349 and 68Ga-PSMA-11, and undergoes PET/CT imaging within the specified time.
Study: NCT06716957

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Schroth exercise
Description: Exercises will be given in lying, sitting and standing positions. In each exercise, elongation of the spine will be ensured and the person will be positioned according to the type of scoliosis. Exercises will be given progressively in supine, prone, side sitting, sitting and standing positions. In each exercise, elongation of the spine will be ensured and the person will be positioned according to the upper and lower extremities. Progress in the exercises will be made positionally by increasing the number of repetitions and the number of rotational breathing during the exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Schroth exercise
Description: Exercises will be given in lying, sitting and standing positions. In each exercise, elongation of the spine will be ensured and the person will be positioned according to the type of scoliosis. Exercises will be given progressively in supine, prone, side sitting, sitting and standing positions. In each exercise, elongation of the spine will be ensured and the person will be positioned according to the upper and lower extremities. Progress in the exercises will be made positionally by increasing the number of repetitions and the number of rotational breathing during the exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic Stabilization exercises
Description: The dynamic neuromuscular stabilization group will receive developmental postures based on developmental kinesiology. It will involve a supine 3month Position, side-lying Position, Quadruped, oblique sitting, bear position, squat Position. Each position will be performed for 30-60 s for five reps, active exercise 5-10 reps under supervision for two days/week, and unsupervised for 3 days/week for 12 weeks
Study: NCT06719635

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Presacral Neurectomy
Description: Laparoscopy will be performed under general anesthesia. Then, nerve plexuses will be identified and freed from their underlying tissue, which contains the left common iliac and middle sacral veins. This will be followed by cauterization and cutting of the nerve plexuses.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fluoroscopically guided Superior Hypogastric Plexus Neurolysis
Description: The patients will receive fluoroscopically guided Superior Hypogastric Plexus Neurolysis using 3 mL of 75% ethanol and Radiofrequency of the Sacral nerve Roots 2-4.
Study: NCT06712719

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LP then HP
Description: Each cross-over phase will be 21 days and consist of a 7-day outpatient, controlled diet period, followed by a 7-day inpatient, controlled diet, balance, and kinetic study period, followed by a second 7-day outpatient, controlled diet period.~LP then HP

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HP then LP
Description: Each cross-over phase will be 21 days and consist of a 7-day outpatient, controlled diet period, followed by a 7-day inpatient, controlled diet, balance, and kinetic study period, followed by a second 7-day outpatient, controlled diet period.~HP then LP
Study: NCT06729112

Intervention type: DIAGNOSTIC_TEST
Intervention: pan immune inflammation value
Description: Using the ratio of neutrophil, monocyte, and platelet counts to lymphocyte count, NLR, MLR, and PLR were calculated. The pan immune inflammation value (PIV) was calculated by multiplying the neutrophil count by the platelet count and the monocyte count, and then dividing the result by the lymphocyte count.

Intervention type: DIAGNOSTIC_TEST
Intervention: pan immune inflammation value
Description: Using the ratio of neutrophil, monocyte, and platelet counts to lymphocyte count, NLR, MLR, and PLR were calculated. The pan immune inflammation value (PIV) was calculated by multiplying the neutrophil count by the platelet count and the monocyte count, and then dividing the result by the lymphocyte count.
Study: NCT06734728

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Profilm Cold Sores
Description: The treatment will consist of daily applications of the product as soon as the first symptoms of an outbreak appear, and until the outbreak subsides, as follows: application every 8 hours, with the possibility of shortening the interval to 6 hours if needed (a maximum of 3-4 applications).